A5080746799- Occupational and environmental lung diseases
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Pleural and Pulmonary Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- MicroRNA in disease regulation
- Extracellular vesicles in disease
- Peptidase Inhibition and Analysis
- RNA modifications and cancer
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Inflammatory Biomarkers in Disease Prognosis
- Tissue Engineering and Regenerative Medicine
- Neuroblastoma Research and Treatments
- Immunotherapy and Immune Responses
- Radiation Dose and Imaging
- Childhood Cancer Survivors' Quality of Life
- Biomarkers in Disease Mechanisms
Chris O’Brien Lifehouse
2016-2025
Shin Kong WHS Memorial Hospital
2025
Taipei Veterans General Hospital
2025
Asbestos Diseases Research Institute
2015-2024
The University of Sydney
2015-2024
Merck & Co., Inc., Rahway, NJ, USA (United States)
2023
Merck (Germany)
2023
Boehringer Ingelheim (India)
2023
Janssen (Switzerland)
2023
PharmaMar (Spain)
2023
The presence of cell-free microRNAs (miRNAs) has been detected in a range body fluids. miRNA content plasma/serum particular proposed as potential source novel biomarkers for number diseases. Nevertheless, the quantification miRNAs from plasma or serum is made difficult due to inefficient isolation and lack consensus regarding optimal reference miRNA. effect haemolysis on normalisation not investigated great detail. We found that levels miR-16, commonly used gene, showed little variation...
Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine inhibitor (TKI) with robust clinical activity in advanced ALK-positive non-small-cell lung cancer, including patients who have failed prior ALK TKIs. Molecular determinants of response to lorlatinib not been established, but preclinical data suggest that resistance mutations may represent biomarker previously treated patients.Baseline plasma and tumor tissue samples were collected from...
Asbestos-induced chronic inflammation is implicated in the pathogenesis of malignant mesothelioma (MM). We have investigated blood neutrophil-to-lymphocyte ratio (NLR), an index systemic inflammation, as a prognostic factor MM patients.Patients with who had therapy at participating institutes were studied. Potential factors such age, gender, performance status, histologic subtype, and baseline laboratory parameters, including NLR, analyzed. Overall survival from commencement was determined...
Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to epidermal growth factor receptor 3 (HER3) attached topoisomerase I inhibitor payload via stable tetrapeptide-based cleavable linker. We assessed the efficacy and safety HER3-DXd in patients with (
The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib a next-generation TKI with preclinical against cancers, including those mutations such as G2032R. Download PDF Research Summary. In this registrational phase 1–2 trial, we assessed efficacy safety repotrectinib patients advanced...
Background Ociperlimab, a novel, humanized monoclonal antibody (mAb), binds to T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) high affinity specificity. Tislelizumab is an anti-programmed cell death protein 1 mAb. We report results from phase I, first-in-human, dose escalation study evaluating the safety, pharmacokinetics (PK), preliminary antitumor activity of ociperlimab plus tislelizumab in patients advanced solid tumors. Methods Eligible...
Fibulin-3 (FBLN3) was recently presented as a promising novel biomarker for malignant pleural mesothelioma (MPM), warranting independent validation studies. ELISA used to measure cellular and secreted FBLN3 in cell lines, plasma of xenograft tumour-bearing mice, from two series MPM non-MPM patients fluid third series. Diagnostic prognostic potential assessed by receiver operating characteristics curve analysis Kaplan–Meier method, respectively. expressed all benign mesothelial lines tested,...
// Marissa Williams 1, * , Michaela B. Kirschner 2, 13, Yuen Yee Cheng 1 Jacky Hanh 3 Jocelyn Weiss 4 Nancy Mugridge Casey M. Wright Anthony Linton 5 Steven C. Kao 6 J. James Edelman 7 Michael P. Vallely 7, 8 Brian McCaughan 9 Wendy Cooper 10 Sonja Klebe 11 Ruby C.Y. Lin 12 Himanshu Brahmbhatt Jennifer MacDiarmid Nico van Zandwijk 2 Glen Reid Asbestos Diseases Research Institute (ADRI), Sydney, Australia Sydney Medical School, The University of Faculty Pharmacy, EnGeneIC Ltd., Lane Cove,...
Although the prognosis of most patients presenting with malignant pleural mesothelioma (MPM) is poor, a small proportion survives long term. We investigated factors associated survival in large patient series. All registered NSW Dust Diseases Board (2002–2009) were included an analysis prognostic using Kaplan–Meier and Cox regression analysis. On basis these analyses, we developed risk score (Prognostic Index (PI)). identified 910 patients: 90% male; histology (epithelioid 60%; biphasic 13%;...